CXR101
Head and Neck Squamous Cell Carcinoma (HNSCC)
Pre-clinicalActive
Key Facts
Indication
Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase
Pre-clinical
Status
Active
Company
About CorriXR Therapeutics
CorriXR Therapeutics is a private, pre-clinical stage biotech founded in 2020 and based in Cambridge, USA. The company is developing an in vivo CRISPR/Cas gene editing platform that targets the NRF2 pathway to reprogram the tumor microenvironment and re-sensitize solid tumors to standard-of-care treatments like chemotherapy and radiotherapy. Its initial focus is on head and neck squamous cell carcinoma (HNSCC), with a pipeline potentially applicable to over 30 squamous cell carcinoma indications. The company's approach combines a novel genetic target with a proven LNP delivery system administered locally to minimize off-target effects.
View full company profileTherapeutic Areas
Other Head and Neck Squamous Cell Carcinoma (HNSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Membrex™ | Metaclipse Therapeutics | Phase 1 |
| VCN-01 | Theriva Biologics | Phase 2 |